{"title":"化脓性汗腺炎放疗后的长期随访。","authors":"Jurr Boer","doi":"10.1159/000517252","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with hidradenitis suppurativa (HS) are still often disappointed with the current treatments offered and there is a clear demand for more effective options. Since the late 1990s there has been a revival in the use of radiotherapy (RT) for different benign diseases, including HS. During the past 20 years one case series and some scattered case reports have described promising results of RT.</p><p><strong>Objectives: </strong>To evaluate the long-term efficacy of RT in early-stage HS.</p><p><strong>Methods: </strong>A postal survey-based long-term follow-up with simple factual questions of partly retrospective and partly contemporary characteristics was performed. Sixty-four patients (96 axillae), diagnosed with mild to moderate HS were irradiated with a orthovoltage unit with 100 kV, 3 mm Al or 200 kV, 0.5 Cu filtering, respectively. Four to six biweekly fractional doses ranging from 0.75 to 1 Gy up to a total dose of 6 Gy in one series, and in chronic cases followed by four daily fractions of 2 Gy up to a total dose of 14 Gy, were given. Late treatment toxicity and the rate of remission of the disease were evaluated.</p><p><strong>Results: </strong>The overall response rate of the survey was 64.1% with 40.6% (26/64) valid, complete questionnaires. In total, 40 axillae were irradiated in these 26 patients. After a median follow-up of 40 years (range 32-52) complete remission of the lesions occurred in 34 of the 40 sites (85%). None of the 26 patients with 40 irradiated sites reported adverse effects at the time of the survey.</p><p><strong>Conclusions: </strong>RT appears to be an effective treatment for early and mild HS in the majority of patients. In this case series, no side effects were reported after a median follow-up period of 40 years.</p>","PeriodicalId":144585,"journal":{"name":"Dermatology (Basel, Switzerland)","volume":" ","pages":"244-250"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000517252","citationCount":"0","resultStr":"{\"title\":\"Long-Term Follow-Up after Radiotherapy of Hidradenitis Suppurativa.\",\"authors\":\"Jurr Boer\",\"doi\":\"10.1159/000517252\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Patients with hidradenitis suppurativa (HS) are still often disappointed with the current treatments offered and there is a clear demand for more effective options. Since the late 1990s there has been a revival in the use of radiotherapy (RT) for different benign diseases, including HS. During the past 20 years one case series and some scattered case reports have described promising results of RT.</p><p><strong>Objectives: </strong>To evaluate the long-term efficacy of RT in early-stage HS.</p><p><strong>Methods: </strong>A postal survey-based long-term follow-up with simple factual questions of partly retrospective and partly contemporary characteristics was performed. Sixty-four patients (96 axillae), diagnosed with mild to moderate HS were irradiated with a orthovoltage unit with 100 kV, 3 mm Al or 200 kV, 0.5 Cu filtering, respectively. Four to six biweekly fractional doses ranging from 0.75 to 1 Gy up to a total dose of 6 Gy in one series, and in chronic cases followed by four daily fractions of 2 Gy up to a total dose of 14 Gy, were given. Late treatment toxicity and the rate of remission of the disease were evaluated.</p><p><strong>Results: </strong>The overall response rate of the survey was 64.1% with 40.6% (26/64) valid, complete questionnaires. In total, 40 axillae were irradiated in these 26 patients. After a median follow-up of 40 years (range 32-52) complete remission of the lesions occurred in 34 of the 40 sites (85%). None of the 26 patients with 40 irradiated sites reported adverse effects at the time of the survey.</p><p><strong>Conclusions: </strong>RT appears to be an effective treatment for early and mild HS in the majority of patients. In this case series, no side effects were reported after a median follow-up period of 40 years.</p>\",\"PeriodicalId\":144585,\"journal\":{\"name\":\"Dermatology (Basel, Switzerland)\",\"volume\":\" \",\"pages\":\"244-250\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000517252\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology (Basel, Switzerland)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000517252\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/6/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology (Basel, Switzerland)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000517252","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:化脓性汗腺炎(HS)患者仍然经常对目前提供的治疗感到失望,显然需要更有效的选择。自20世纪90年代末以来,对包括HS在内的各种良性疾病使用放射治疗(RT)的情况有所恢复。在过去的20年里,一个病例系列和一些零散的病例报告描述了RT治疗的良好结果。目的:评价RT治疗早期HS的长期疗效。方法:采用邮政调查为基础的长期随访,采用部分回顾性和部分当代特征的简单事实性问题。64例(96腋下)诊断为轻中度HS,分别用100 kV, 3 mm Al或200 kV, 0.5 Cu滤波的正压单元照射。在一个系列中,每两周给予4至6次分次剂量,剂量范围为0.75至1戈瑞,直至总剂量为6戈瑞;在慢性病例中,随后给予4次每日分次剂量,剂量为2戈瑞,直至总剂量为14戈瑞。评估治疗后期毒性和疾病缓解率。结果:调查总有效率为64.1%,有效、完整问卷40.6%(26/64)。26例患者共照射40个腋窝。中位随访40年(32-52年)后,40个部位中34个(85%)病灶完全缓解。在调查时,26名接受40个部位辐照的患者中没有人报告有不良反应。结论:对大多数早期和轻度HS患者,RT似乎是一种有效的治疗方法。在这个病例系列中,中位随访期为40年,无副作用报告。
Long-Term Follow-Up after Radiotherapy of Hidradenitis Suppurativa.
Background: Patients with hidradenitis suppurativa (HS) are still often disappointed with the current treatments offered and there is a clear demand for more effective options. Since the late 1990s there has been a revival in the use of radiotherapy (RT) for different benign diseases, including HS. During the past 20 years one case series and some scattered case reports have described promising results of RT.
Objectives: To evaluate the long-term efficacy of RT in early-stage HS.
Methods: A postal survey-based long-term follow-up with simple factual questions of partly retrospective and partly contemporary characteristics was performed. Sixty-four patients (96 axillae), diagnosed with mild to moderate HS were irradiated with a orthovoltage unit with 100 kV, 3 mm Al or 200 kV, 0.5 Cu filtering, respectively. Four to six biweekly fractional doses ranging from 0.75 to 1 Gy up to a total dose of 6 Gy in one series, and in chronic cases followed by four daily fractions of 2 Gy up to a total dose of 14 Gy, were given. Late treatment toxicity and the rate of remission of the disease were evaluated.
Results: The overall response rate of the survey was 64.1% with 40.6% (26/64) valid, complete questionnaires. In total, 40 axillae were irradiated in these 26 patients. After a median follow-up of 40 years (range 32-52) complete remission of the lesions occurred in 34 of the 40 sites (85%). None of the 26 patients with 40 irradiated sites reported adverse effects at the time of the survey.
Conclusions: RT appears to be an effective treatment for early and mild HS in the majority of patients. In this case series, no side effects were reported after a median follow-up period of 40 years.